From the Journals

COVID-19 antibody response not reduced with diabetes

Publish date: October 20, 2020

 

A version of this article originally appeared on Medscape.com.

Pages

Recommended Reading

Exercise cuts diabetes death risk by a third in two studies
Federal Practitioner
Higher glycemic time in range may benefit T2D patients
Federal Practitioner
Geriatric patients: My three rules for them
Federal Practitioner
AHA scientific statement highlights cardiorenal benefit of new diabetes drugs
Federal Practitioner
Dapagliflozin’s CKD performance sends heart failure messages
Federal Practitioner
Time to screen for liver disease in type 2 diabetes?
Federal Practitioner
PPIs associated with diabetes risk, but questions remain
Federal Practitioner
Evaluation of Glycemic Control and Cost Savings Associated With Liraglutide Dose Reduction at a Veterans Affairs Hospital
Federal Practitioner
T2D treatments create tension between glycemic and cardiovascular goals
Federal Practitioner
Recall widens for diabetes drug metformin
Federal Practitioner